ATE91630T1 - Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren. - Google Patents

Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.

Info

Publication number
ATE91630T1
ATE91630T1 AT90904636T AT90904636T ATE91630T1 AT E91630 T1 ATE91630 T1 AT E91630T1 AT 90904636 T AT90904636 T AT 90904636T AT 90904636 T AT90904636 T AT 90904636T AT E91630 T1 ATE91630 T1 AT E91630T1
Authority
AT
Austria
Prior art keywords
prevention
pharmaceutical composition
papillomavirus
cure
induced tumors
Prior art date
Application number
AT90904636T
Other languages
English (en)
Inventor
Guerrino Meneguzzi
Richard Lathe
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE91630T1 publication Critical patent/ATE91630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90904636T 1989-03-06 1990-03-06 Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren. ATE91630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8902897A FR2643817B1 (fr) 1989-03-06 1989-03-06 Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
PCT/FR1990/000151 WO1990010459A1 (fr) 1989-03-06 1990-03-06 Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus

Publications (1)

Publication Number Publication Date
ATE91630T1 true ATE91630T1 (de) 1993-08-15

Family

ID=9379397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90904636T ATE91630T1 (de) 1989-03-06 1990-03-06 Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.

Country Status (9)

Country Link
EP (1) EP0462187B1 (de)
JP (1) JP2926270B2 (de)
AT (1) ATE91630T1 (de)
CA (1) CA2050304C (de)
DE (1) DE69002325T2 (de)
DK (1) DK0462187T3 (de)
ES (1) ES2058898T3 (de)
FR (1) FR2643817B1 (de)
WO (1) WO1990010459A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
EP0772689B1 (de) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retrovirale vektoren mit verminderter rekombinationsrate
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
NZ293461A (en) * 1994-09-22 1998-04-27 Merck & Co Inc Dna encoding human papillomavirus type 6a, compounds derived therefrom
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US7189513B2 (en) 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
CA2675355C (en) 2007-01-30 2015-04-28 Transgene S.A. Papillomavirus vaccine
PL2382474T3 (pl) 2009-01-20 2015-08-31 Transgene Sa Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
HRP20140262T1 (hr) 2009-04-17 2014-04-25 Transgene Sa Biomarker za praä†enje pacijenata
RU2011148791A (ru) 2009-05-12 2013-06-20 Трансген Са Иммортализованные линии клеток птиц и их применение
MX337287B (es) 2009-07-10 2016-02-22 Transgene Sa Biomarcador para seleccionar pacientes y metodos relacionados.
RU2012106760A (ru) 2009-07-21 2013-08-27 Трансген Са Ферментативная композиция для ферментативного расщепления куриного эмбриона
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
ES2753364T3 (es) 2014-12-01 2020-04-08 Transgene Sa Formulaciones líquidas estables de virus vaccinia
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物

Also Published As

Publication number Publication date
CA2050304C (fr) 2002-01-22
WO1990010459A1 (fr) 1990-09-20
DK0462187T3 (da) 1993-10-18
FR2643817A1 (fr) 1990-09-07
JPH05503282A (ja) 1993-06-03
JP2926270B2 (ja) 1999-07-28
DE69002325T2 (de) 1993-12-02
FR2643817B1 (fr) 1993-12-17
EP0462187B1 (de) 1993-07-21
DE69002325D1 (de) 1993-08-26
CA2050304A1 (fr) 1990-09-07
EP0462187A1 (de) 1991-12-27
ES2058898T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE328068T1 (de) Papillomavirus vakzine
AU5417079A (en) Recombinant dna molecules
DE69435331D1 (de) Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
ES2191663T3 (es) Virus recombinante de la viruela porcina.
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE237691T1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69840637D1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE102005055128A1 (de) Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
ZA95968B (en) Interferon alpha/beta binding protein its preparation and use
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
ATE80306T1 (de) Mittel zur absorptionsverbesserung von proteinen.
WO2000014112A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE415419T1 (de) Inaktivierte zytokine zur immunisierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time